Science
Clover is initiating sixth vaccine trial in China, COVID-19
The sixth Chinese manufacturer of a possible COVID-19 vaccine in Canada Clover Biopharmaceuticals launched a trial in Australia to test the vaccine with boosters on Friday to go into human testing.
Throughout the health crises, China and the US face simultaneous attempts to effectively authorize vaccines and to manufacture large-scale vaccines later this year.
There are no licensed coronavirus vaccines or therapies at this time, but approximately a dozen vaccines are monitored worldwide.
The virus came into existence at the end of last year in Wuan, China, and has spread to over 450,000 people worldwide since then.
A growing number of cases have forced the authorities to examine the genome of an alternative strain at the Beijing capital of China.
Two boosters, or adjuvants, from British GSK and U.S. Dynavax in conjunction with its candidate shot, SCB-2019, will be tested by a Clover 's trial that includes approximately 150 adult and elderly patients, according to the Chinese firm.
China's Biological CanSino, Sinopharm and the Wuhan Institute of Biological Products, AstraZeneca, Moderna and the CureVac in Germany, are already testing vaccines.
Clover stated that his initial study safety data were expected in August of this year and aimed at starting further studies by the end of the year.
Its vaccine is based in combination with adjuvants on proteins known as antigens.
GSK, the world's largest vaccine producer, has shunned the development of its vaccine and focuses instead on contributing its additional expertise to the worldwide vaccine industry.
To order to improve the immune response, adjuvants or efficacy additives are added to certain vaccines to increase their immune immunity.
The booster CpG 1018 was developed as an Adjuvant to the Hepatitis B vaccine of the U.S. corporation and was tested on CLOVER 's shot.
Source: Reuters
